Recombinant antibody technology

The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is primarily addressed to scientists working on recombinant antibodies as well as clinicians involved with antibody-based therapies. 

Recombinant antibodies offer a number of potential benefits over monoclonal antibodies, as they can be derived from almost any animal in which the immunoglobulin DNA sequences have been described. This aspect of recombinant antibody technology is of particular benefit, as biomarkers for disease diagnosis are often proteins and peptides, which are highly conserved in animals closely related to humans. This can be a particular problem in mice, which frequently develop tolerance for the immunizing antigen, rendering traditional monoclonal antibody development to... 

Advances in tumor biology, recombinant antibody technology, and radio synthetic chemistry have led to a flurry of activity in the development and clinical application of endoradiotherapeutic agents. However, it is important to bear in mind that radionuclide therapy is actually not a new concept, having been used in patients for more than 60 years. A number of textbooks provide excellent chronicles of early efforts in radionuclide therapy (Spencer 1978 Harbert 1987 Spencer et al. 1987). A notable example is sodium [ ijiodide, which has been utilized for the treatment of hyperthyroidism and thyroid carcinomas and remains the most widely utilized targeted radiotherapeutic in current clinical use. Radiocolloids such as those labeled with either Au or have been used for more than 50 years for the treatment of diseases such as malignant pleural effusions and intraperitoneal tumors. 

Biotech products based on recombinant DNA, gene expression or hybridoma/monoclonal antibody technologies. 

During the 1980s, rapid developments in the areas of recombinant DNA technology and monoclonal antibody technology contributed to a greater depth of understanding of cytokine biology ... 

Recombinant DNA technology has provided an alternative (and successful) route of reducing the innate immunity of murine monoclonals. The genes for all human immunoglobulin sub-types have been cloned, and this has allowed generation of various hybrid antibody structures of reduced immunogenicity. 

Figure 13.9 Production of chimaeric (a) and humanized (b) antibodies (via recombinant DNA technology). Chimaeric antibodies consist of murine monoclonal VH and VL domains grafted onto the Fc region of a human antibody. Humanized antibody consists of murine CDR regions grafted into a human antibody...

The diversity of antibodies can be increased further with phage display libraries and recombinant DNA technology. In recombinant DNA... 

---